Recent Updates
Daraxonrasib Improves Survival Outcomes in Previously Treated Metastatic PDAC
Therapeutic options for metastatic pancreatic ductal adenocarcinoma (PDAC) remain limited, with second-line treatments typically yielding modest benefit. Activation of the RAS pathway, most commonly driven by KRAS mutations, occurs in the vast majority of PDAC cases and represents a critical oncogenic dependency.
June 1, 2026
North American Enrollment in Clinical Trials
Clinical Trials

North American Enrollment in Clinical Trials

Dr. Ming-Hei Tai, PharmD April 15, 2026
  • 1
  • 2

What are you looking for?